Answers are grounded in this paper and cite their sources.
Anti‐IgLON5 disease is a rare neurological disorder with overlapping autoimmune and neurodegenerative features, often leading to delayed diagnosis due to phenotypic heterogeneity. Early identification of immune‐dominant cases is crucial, as they may respond to immunotherapy. We report a 67‐year‐old male presenting with progressive bulbar dysfunction, sleep‐disordered breathing, and intermittent hypercapnic respiratory failure over 6 months. Structural neuroimaging and cerebrospinal fluid analysis were unremarkable. FDG‐PET brain imaging suggested a neurodegenerative pattern; however, preserved dopaminergic uptake on 18F‐DOPA PET did not support a significant presynaptic nigrostriatal dopaminergic deficit. Polysomnography confirmed severe obstructive sleep apnea with nocturnal hypoventilation. Serum anti‐IgLON5 antibodies were very strongly positive on a tissue‐based assay using indirect immunofluorescence at a 1:10 dilution and were subsequently confirmed by a cell‐based assay. CSF anti‐IgLON5 antibody testing was not performed. Serum neurofilament light polypeptide was measured by sandwich enzyme‐linked immunosorbent assay (ELISA) and was reported as “not detected”; the laboratory did not provide a numerical lower limit of detection. The patient was treated with intravenous methylprednisolone, intravenous immunoglobulin, and rituximab, resulting in clinically meaningful improvement. This case highlights the importance of recognizing immune‐dominant anti‐IgLON5 disease. Multimodal imaging and biomarkers can differentiate it from neurodegenerative disorders, enabling early immunotherapy and improved outcomes.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: